Treatment of the most common non-Hodgkin's lymphoma FDA accelerated approval of the "enhanced version" antibody therapy on the market.

DLBCL is the most common type of non-Hodgkin's lymphoma in adults society 44, characterized by rapidly growing malignant B-cell tumors in lymph nodes, spleen, liver, bone marrow, or other organs.
is an invasive disease, with about one-third of patients not responding to initial treatment or relapsing later.
, about 10,000 patients are diagnosed each year with relapsed/refrectable DLBCL that is not suitable for ASCT.
2010, MorphoSys acquired a global exclusive interest in the development of tafasitamab from Xencor.
Tafasitamab uses Fc domain modification technology called XmAb to improve the affinity of antibodies with Fc receptors by 40 times, thus better activating immune cells such as congenital killer cells (NK cells), macrophages, and cytotoxicity (ADCC) mediated by antibody-dependent cells, and antibody-dependent cytophageal (ADCP) mediate.
fda previously granted Monjuvi and Lynamide combination therapy relapse/refracilable DLBCL fast-track and breakthrough therapy identification and priority review eligibility.
XmAb technology platform is able to enhance the multiple characteristics of antibodies by transforming the Fc domain (Photo: Xencor.com) FDA approval is based on data from MorphoSys' open label, multi-center, single-group Phase 2 clinical trial L-MIND.
results showed that Monjuvi was associated with lynamide, achieving a total mitigation rate (ORR) of 55 percent, including a full mitigation rate of 37 percent and a partial mitigation rate of 18 percent.
medium mitigation duration (mDOR) is 21.7 months.
: s1. FDA Approves Monjuvi ® (tafasitamab-cxix) in Group With Lenalidomide for The Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Lymphoma (DLBCL). Retrieved 2020-08-01, from ®-tafasitamab-cxix-Group-Lenalidomide-Treatment.